Home | Contact Us 

Online Catalog

View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at

How Can We Help You?
Click here to contact us!


Sepragen Corporation Launches Quantasep® 'BioTech Software' For Microsoft® Windows NT®

Union City, CA, March 22, 2000 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) a technology developer of equipment and supplies for radial flow chromatography (RFC) applications, today announced the launch of its QuantaSep 3.X bioseparations control software for Windows NT.

This dynamic new software powers Sepragen’s line of pilot and process scale chromatography systems. These systems are being used by Sepragen’s biotech customers to “scale-up” their processes in order to produce purified material for later stage clinical trials and biotech drug manufacturing. Sepragen’s biotech customers include, Smith-Kline Beechman, Schering Plough, Baxter International, Glaxo Wellcome, Chiron, Merck and Roche Diagnostics.

Vinit Saxena, Sepragen’s Chairman and CEO stated, “Our technologies enable our biotech and gene therapy customers to produce large quantities of product quickly, for clinical testing, which accelerates their time to market. More established customers find that our technology and products enable cost-effective, predictable “scale-up” of their purification process for commercial launch.”

Sepragen Corporation develops and markets technology along with equipment and supplies for process chromatography applications. Sepragen has developed a number of patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The company holds over 14 issued patents relating to its core technology.

Return to News Archives main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2020 Sepragen Corporation. All rights reserved. (510) 475-0650